Clinical Trial Update: Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma

View source ↗

Summary

The expanded access program for Elranatamab in adults with relapsed/refractory multiple myeloma has been updated and is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Elranatamab (elranatamab)

Snippet

Sponsor: Pfizer | Conditions: Multiple Myeloma | Status: NO_LONGER_AVAILABLE